A tubulin binding molecule drives differentiation of acute myeloid leukemia cells

Despite much progress in developing better drugs, many patients with acute myeloid leukemia (AML) still die within a year of diagnosis. This is partly because it is difficult to identify therapeutic targets that are effective across multiple AML subtypes. One common factor across AML subtypes is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Thomas R., Vuorinen, Aini, Josa-Culleré, Laia, Madden, Katrina S., Conole, Daniel, Cogswell, Thomas J., Wilkinson, Isabel V.L., Kettyle, Laura M., Zhang, Douzi, O’Mahony, Alison, Gracias, Deanne, McCall, Lorna, Westwood, Robert, Terstappen, Georg C., Davies, Stephen G., Tate, Edward W., Wynne, Graham M., Vyas, Paresh, Russell, Angela J., Milne, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385704/
https://www.ncbi.nlm.nih.gov/pubmed/35992086
http://dx.doi.org/10.1016/j.isci.2022.104787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385704/
https://www.ncbi.nlm.nih.gov/pubmed/35992086
http://dx.doi.org/10.1016/j.isci.2022.104787

Ejemplares similares